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a b s t r a c t
28Antiseizure medications (ASM) may contribute to adverse fetal outcomes in pregnant women with epi-
29lepsy (WWE). Folate processing (Methylenetetrahydrofolate reductase, MTHFR) gene abnormalities are
30common in women with epilepsy and depression. L-methylfolate supplements may bypass MTHFR defi-
31ciencies, yet their use in WWE during gestation or on fetal development is not well studied. We examine
32pregnancy histories of three WWE who supplemented with either folate or L-methylfolate and methyl-
33cobalamin (methylated B12) during pregnancies. Their pregnancy outcomes improved with L-
34methylfolate and methylcobalamin supplementation. L-methylfolate and methylcobalamin supplemen-
35tation merits further study in WWE who have MTHFR mutations, fertility, recurrent miscarriage and
36or depression histories.






43 Women with epilepsy (WWE) are more likely to have problems
44 with conception, gestation and delivery of normal infants [1]. In
45 addition, WWE remain at higher risk of mood dysfunction and
46 depression [2]. Medications that lower burdens of depression,
47 bipolar disorder and epilepsy may have teratogenic effects
48 [1,2,4]. How antiseizure medication (ASM) might alter teratogenic-
49 ity remains incompletely understood, however, in recent work
50 ASM induction of de novo genetic variants is unlikely [5]. ASM or
51 mood stabilizing medications such as carbamazepine (CBZ) and
52 valproic acid (VPA) have been shown to increase risk of fetal neural
53 tube defects (NTD) including spina bifida [1,3]. CBZ and VPA may
54 include altered folate mechanisms, specifically decreases in levels
55 of 5-formyl- and 10-formyltetrahydrofolate, which in turn may
56 disrupt DNA methylation and histone acetylation pathways which
57 may then alter cell division and migration [3,6].
58 Folate supplementation of up to 4 mg during gestation remains
59 standard of care for WWE in the USA [1]. Use of folate supplements
60from pre-conception to delivery decreases the odds ratio of NTD
61development from 1.6 (95% CI 0.8–3.1) to 1.2 (95% CI 0.4–4.0)
62[1,7–10], however folate mitigation of teratogenic effects due to
63ASM have not been well documented [11,12]. Supplementary folate
64in women taking CBZ and VPA for instance, does not decrease rates
65of spina bifida [13]. Our epilepsy community remains focused on
66ASM that have the lowest risk of use in pregnancy. If we have to
67use a particularly teratogenic ASM in pregnancy such as VPA, the
68strategies to limit fetal risk often jeopardize maternal seizure con-
69trol, particularly if first trimester doses are lowered or risky and
70quick substitution for less effective ASM occurs.
71A potential risk factor for NTD can occur in folate pathways,
72specifically, a polymorphism that codes for 5,10-
73methylenetetrahydrofolate reductase (MTHFR) [6,14]. This gene
74makes folate bioavailable through methylation, permitting homo-
75cysteine to convert to methionine, a critical step for normal protein
76synthesis. If MTHFR cannot methylate folate, common findings in
77women who supplement with folic acid are elevations in serum
78folate. Polymorphisms in the MTHFR gene at C677T for both the
79homozygous (TT) and heterozygous (CT) genotypes are increased
80in women with genetic generalized epilepsies when compared to
81a woman without epilepsy, they are less well studied in women
82with focal epilepsy [6,15]. Many women with generalized epilepsy
83show superior control of their epilepsy when using VPA yet as a
84community we try to avoid this drug in women of reproductive
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85 age due to side effect profiles including known teratogenicity. VPA
86 teratogenicity may be further exacerbated in women who have
87 defects in their MTHFR pathways [6].
88 Dietary folate, combined with dietary vitamin B12 are both
89 required in converting homocysteine to methionine and ultimately
90 lead to protein synthesis. [16] When these pathways do not func-
91 tion efficiently, homocysteine may elevate; hyperhomocysteinema
92 in pregnancy and in neonates may correlate with worse fetal out-
93 comes. [16,17] Additional risks of folate pathways not functioning
94 well occur in the setting of limited bioavailable vitamin B12. [17]
95 5-methyltetrahydrofolate may be available as L-methylfolate
96 and is used in the USA for the treatment of depression [18,19].
97 The supplement has few known adverse effects and bypasses
98 MTHFR gene pathways, in essence becoming bioavailable when
99 gene efficiency is otherwise compromised. In patients with MTHFR
100 gene defects, data suggests prenatal supplementation with L-
101 methylfolate is more successful at increasing bioavailable folate
102 concentrations than unmethylated folic acid [20]. Furthermore,
103 infertility-based supplementation of methylated folates in women
104 and men with C677T MTHFR mutations may help with successful
105 conceptions and gestations [20].
106 Somewhat remarkably, whether methylated versions of folate
107 and vitamin B12 (methylcobalamin) taken by WWE helps avoid
108 depression, seizure, fertility, or adverse fetal outcomes like spina
109 bifida during pregnancy remains unknown. In this observational
110 report we document pregnancy, seizure and mood histories with
111 and without L-methylfolate or methylcobalamin for three women
112 with epilepsy with known MTHFR mutations.
113 2. Case reports
114 After informed consent patients were interviewed regarding
115 pregnancy, conception, miscarriage, mood and child developmen-
116 tal histories. Data are summarized on Table 1. No statistical testing
117 was performed. Key findings include pregnancy outcomes on var-
118 ied supplement or medication doses. Standardized practice models
119 of adjusting antiseizure medication doses through serum drug
120 levels checked every 6 weeks during gestation as were referrals
121 to high risk Maternal Fetal Medicine specialists for surveillance
122 ultrasounds during gestations and peri-delivery care. If available,
123 homocysteine and folate levels are documented, these were not
124 serially surveyed. Seizures did not occur during any of the success-
125 ful pregnancies, nor were they thought to be causative of any of the
126 miscarriages.
127 3. Discussion
128 3.1. Notes on cases
129 Patients one and two adopted methylated folate and methyl-
130 cobalamin/injected B-12 supplementation after recurrent miscar-
131 riage or conception failures. We have no way of proving if these
132 two supplements helped with subsequent successful pregnancies
133 and deliveries, though successful pregnancies and deliveries sug-
134 gested benefit. Importantly we did not see adverse outcomes. Par-
135 ticularly notable is the gestation failure for patient one’s fourth
136 pregnancy, which occurred on methylated folate though off of vita-
137 min B12 injection therapies. All of the successful pregnancies
138 occurred while on methylated folate and either injected or methy-
139 lated B12 supplements in addition to standard prenatal multivita-
140 min supplements.
141 Patient three’s use of L-methylfolate therapies proved funda-
142 mental to her desire to even pursue pregnancy. Specifically, prior
143 to her L-methylfolate supplementation, she was recurrently trea-
144 ted with electroconvulsive therapies for refractory depression
145and had not considered pregnancy. With L-methylfolate success
146in treating her depression, she no longer required ECT, and both
147her mood and epilepsy remained controlled during
148pregnancy and postpartum.
1493.2. Limitations
150This study has a small sample size, and as such miscarriage
151rates may be no different than chance. Folate and homocysteine
152levels were not serially surveyed in either the mothers or children,
153the children remain young at time of writing, and without neu-
154ropsychological assessment. Similarly, mood batteries in the moth-
155ers pre and post methylated folate or methylcobalamin
156supplementation were not done.
1573.3. Risks of folic acid and B12 elevations in pregnancy
158Limited data exists on risks of elevated folate during pregnancy.
159One study documents a U-shaped risk of third-trimester B12 and
160folate levels in mothers with a risk of autism spectrum disorders
161(ASD) in their offspring when levels are either low or very high
162[21]. Rhagavan et al. found no risk of maternal folate and MTHFR
163genotype status on ASD outcomes. Their study did not look at
164cohort use during gestation of methylated vs non-methylated ver-
165sions of B12 and/or folate.
1663.4. Implications
167Many patients with genetic generalized epilepsies remain con-
168trolled on VPA, including during pregnancy [1]. Women on VPA
169therapies during pregnancy have the highest risk of adverse fetal
170outcomes [1]. Given MTHFR mutations are common in women
171with generalized epilepsy, should they wish to conceive and if they
172have to remain on VPA, pharmacogenetic targeting and preconcep-
173tion and pregnancy supplementation with L-methylfolate and
174methylcobalamin if MTHFR defects are present should be studied
175[19]. Similarly, women who were switched off of VPA pre-
176conception due to teratogenic concerns, that went on to have
177recurrent fetal loss or conception failures, should also be consid-
178ered candidates for a similar workup and therapy approach.
179Regardless of a generalized epilepsy diagnosis, our study sug-
180gests women with a variety of ofepilepsy classifications with/with-
181out mood disorders with recurrent conception failures, irrespective
182of medication profiles, could be screened for MTHFRmutations and
183if abnormal, consider supplementation with both methylcobal-
184amin and L-methyfolate. We have not found homocysteine levels
185useful, nor folate levels practical in screening. Folate is often ele-
186vated in patients with MTHFR defects on supplemental folate and
187may be falsely reassuring. Those patients, however, merit formal
188study. Specifically with outcomes looking at safety, seizure con-
189trols, dosage of methylated vitamins, gestation success, incidence
190of neonatal stroke or hypoxic ischemic issues, use of supplements
191during breast feeding, incidence of spina bifida along with longer
192term neonatal and neurodevelopmental outcomes, including ASD.
193In addition, measurements of depression preconception, during
194gestation, and post-partum could also be checked.
1954. Conclusion
196After either recurrent fertility setbacks or depression in prior
197pregnancies, three WWE with known MTHFR mutations had suc-
198cessful pregnancies when supplementing with L-
199methylfolate and methylated folate or methylcobalamin. Fetal
200and maternal risks of exposure to methylated vitamins are not well
201known. Prospective studies of methylated folate and methylcobal-
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202 amin in WWE with/without mood disorders and known MTHFR
203 mutations and infertility or recurrent fetal loss, or females admin-
204 istered folate altering ASM such as VPA during pregnancy are
205 warranted.
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